SCHEMBL5136579

SCHEMBL5136579

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
CRHR1 P34998 6/20 0.41
TSHR P16473 3/20 0.41
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MDM2 Q00987 4/20 0.40
RORC P51449 1/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135363 0.96 C5AR1 (0.44) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5136901 0.94 C5AR1 (0.46) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5137404 0.93 CRHR1 (0.43) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5137477 0.91 CRHR1 (0.43) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5135570 0.91 C5AR1 (0.48) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5138025 0.91 C5AR1 (0.47) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5136220 0.90 C5AR1 (0.46) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5135106 0.90 C5AR1 (0.47) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5136173 0.90 C5AR1 (0.47) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL5137122 0.89 MEN1 (0.46) C5AR1CRHR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed